Literature DB >> 7681505

Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A.

W Auch-Schwelk1, C Bossaller, S Götze, J Thelen, E Fleck.   

Abstract

We wished to characterize the altered reactivity of vascular smooth muscle and endothelial cells in rat aorta during chronic treatment with cyclosporin. Male adult rats were treated orally for 6 weeks with either cyclosporin A (30 mg/kg/day in 1 ml olive oil, n = 9) or with vehicle alone (n = 10). Rings of isolated thoracic aorta were mounted in organ chambers to measure the change in isometric force in response to smooth muscle-contracting drugs and endothelium-dependent and independent vasodilators. Contractions to potassium chloride (20-80 mM) were markedly reduced in cyclosporin-treated rats. Contractions to phenylephrine (10(-10)-10(-6) M) were reduced at high concentrations (> or = 10(-7) M); those to endothelin-1 (10(-10)-10(-7) M) were not significantly altered. In contrast, contractions to angiotensin II (AII 10(-9)-10(-6) M) were significantly augmented. Endothelium-dependent relaxations to acetylcholine (ACh 10(-8)-10(-5) M) or ADP (10(-7)-10(-5) M) were reduced in cyclosporin-treated rats; endothelium-independent relaxations to SIN-1 (10(-7)-10(-5) M) and atrial natriuretic peptide (ANP 10(-10)-10(-7) M) remained unaffected. Thus, chronic treatment with cyclosporin affects both endothelium-dependent vasodilation and vascular smooth muscle contraction in rat aorta depending on the stimulus applied. The enhanced response to AII and the reduced release of endothelium-derived relaxing factor (EDRF) may contribute to augmented vascular tone and further damage to the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681505     DOI: 10.1097/00005344-199303000-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

2.  Coronary vasomotor responses in cyclosporine-treated piglets.

Authors:  G Berkenboom; D Brékine; P Unger; B Gulbis; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

3.  Effect of dietary supplementation with fish oil on cyclosporine A-induced vascular toxicity.

Authors:  G Berkenboom; D Brékine; P Unger; M Richelle; Y Carpentier; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

4.  Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.

Authors:  M Lassila; P Finckenberg; A K Pere; L Krogerus; J Ahonen; H Vapaatalo; M L Nurminen
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Vascular remodelling in intramyocardial resistance vessels in hypertensive human cardiac transplant recipients.

Authors:  J T Jenkins; J J Boyle; I C McKay; D Richens; A R McPhaden; G B Lindop
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

6.  Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment.

Authors:  F Cottet-Maire; P V Avdonin; E Roulet; T M Buetler; N Mermod; U T Ruegg
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

7.  Chronic treatment with cyclosporine A in New Zealand rabbit: aortic and erectile tissue alterations.

Authors:  E Ragazzi; C Meggiato; A Chinellato; G Italiano; F Pagano; A Calabrò
Journal:  Urol Res       Date:  1996

8.  Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity.

Authors:  A Lo Russo; A C Passaquin; P André; M Skutella; U T Rüegg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.